Repurposing Rotavirus Vaccines for Intratumoral Immunotherapy can overcome Resistance to Immune Checkpoint Blockade
Science Translational Medicine, 23 octobre 2019
https://stm.sciencemag.org/content/11/515/eaat5025
Tala Shekarian1,2,3,4, Eva Sivado1,2, Anne-Catherine Jallas1,2, Stéphane Depil1,2,3, Janice Kielbassa5, Isabelle Janoueix-Lerosey6,7, Gregor Hutter4, Nadège Goutagny1,2, Christophe Bergeron2,8, Alain Viari5,9, Sandrine Valsesia-Wittmann*1,2,10, Christophe Caux*1,2, Aurélien Marabelle*2,8,11,12
1 Centre de Recherche en Cancérologie de Lyon (CRCL), UMR INSERM U1052 CNRS 5286 Université de Lyon, 69008, Lyon, France
2 Centre de Lutte contre le Cancer Léon Bérard, 69008, Lyon, France
3 Université Claude Bernard Lyon 1, 69100 Villeurbanne France
4 University Hospital Basel, 4031, Basel, Switzerland
5 Synergie Lyon Cancer, Plateforme de bioinformatique ‘Gilles Thomas’, Centre Léon Bérard, 69008, Lyon, France
6 Institut Curie, PSL Research University, Inserm U830, 75005, Paris, France
7 SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, 75005, Paris, France
8 Institut d’Hématologie et d’Oncologie Pédiatrique, Centre Léon Bérard, 69008, Lyon, France
9 Equipe Erable, INRIA Grenoble-Rhône-Alpes, 38330, Montbonnot-Saint Martin, France.
10 INSERM UA8, 69008, Lyon, France
11 Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), 94805, Villejuif, France
12 INSERM U1015, Gustave Roussy, 94805, Villejuif, France